THE LIPID DEBATE: WHAT S NEW? Dr Detloff Rump

Similar documents
Statins in the elderly : Is there a rationale?

Changing lipid-lowering guidelines: whom to treat and how low to go

The All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.

Challenges of diabetes

Modern Lipid Management:

General Public Release. Do Zebras get ulcers?

Fasting or non fasting?

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.

Table of Contents / Agenda

LDL cholesterol and cardiovascular outcomes?

Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Weigh the benefit of statin treatment: LDL & Beyond

Cancer: Past, Present and Future View from the Korean market

LIST OF ABBREVIATIONS

Supplementary appendix

Best Lipid Treatments

Smoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017

CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM

An example of a systematic review and meta-analysis

APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES

When it comes to the FIELD study, what is...is

Page 1. Disclosures. Background. No disclosures

The role of statins in patients with arterial hypertension

Genomic medicine and the insurance industry. Christoph Nabholz, CRO Assembly, 31 May 2018

The TNT Trial Is It Time to Shift Our Goals in Clinical

Lipoprotein Particle Profile

Update on Cholesterol Management: The 2013 ACC/AHA Guidelines

GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Calculating RR, ARR, NNT

How would you manage Ms. Gold

2013 Lipid Guidelines Practical Approach. Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS

Cholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation

Lessons from Recent Atherosclerosis Trials

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

CARDIOVASCULAR HEALTH LIVING A HEART HEALTHY LIFE. Matt Handley MD Group Health Physicians

Young high risk patients the role of statins Dr. Mohamed Jeilan

Cancer changing landscape in Asia

Phytosterol/stanol enriched foods

Inhibition of PCSK9: The Birth of a New Therapy

Diabetic Dyslipidemia

2014 Cholesterol Guidelines

New Strategies for Lowering LDL - Are They Really Worth It?

A loss-of-function variant in CETP and risk of CVD in Chinese adults

2014/10/20. Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals

Review of guidelines for management of dyslipidemia in diabetic patients

Cardiovascular Complications of Diabetes

SEX LIES CHOLESTEROL

Best Practices in Cardiac Care: Getting with the Guidelines

QUESTIONS ANSWERED BY

Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist

Preventive Cardiology

Diabetes Mellitus: A Cardiovascular Disease

Lipids, pt. 1. Feb. 3, Bio 28: Nutrition Instructor: Paul Nagami Laney College

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Hae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.

Approach to Dyslipidemia among diabetic patients

Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Ten Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)

Attainment of Combined Optimal Lipid Values With the Use of Niacin

Scientific conclusions

Prof. Peskin's DPA Scan & Advanced Lipid Analysis

Traitements associés chez l hypertendu: Statines, Aspirine

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Imaging-Guided Statin Allocation: Seeing Is Believing

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Il rischio residuo nella persona con diabete: come individuarlo e come trattarlo?

Since the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT

ATP IV: Predicting Guideline Updates

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

Hypertension and Cholesterol in the Elderly

Roles of Non-HDL Cholesterol in Risk Assessment and Treatment

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Macrovascular Management. What s next beyond standard treatment?

dr. Giuseppe Marazzi None conflict of interest

Use of Subgroups to Rescue a Trial or Improve Benefit-Risk

Statinsshould be in the water supply. Lipid Drug Therapy: Use in Special Populations. Objectives. TSHP 2014 Annual Seminar 1

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Cardiovascular outcomes trials with statins in diabetes

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

Aggressive Lipid Management for Diabetes

Insulin resistance: targeting dyslipidemia beyond the LDL-cholesterol. Disclosures: Presentation outline

Statin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Medical evidence suggests that

Transcription:

THE LIPID DEBATE: WHAT S NEW? Dr Detloff Rump

Agenda The Statin debate The TChol/LDL/HDL/Trig debate The ratio debate Conclusions 2

Statins 3

There is an academic debate and it is not concluded 4

..and the debate is about. https://theconversation.com/bmj-vs-the-lancet-there-are-no-winners-in-the-statins-war-65593 5

..and the debate is about. https://theconversation.com/bmj-vs-the-lancet-there-are-no-winners-in-the-statins-war-65593 6

Firstly: How effective are statins? 7

How does this stack up? 8

So there are benefits, but they seem limited http://www.bendbulletin.com/health/4954532-151/weighing-risks-and-rewards-of-statins 9

Secondly: Are statins safe? There are doubts https://therenegadepharmacist.com/should-you-take-statinswhat-happens-to-your-body-when-you-take-statins/ 10

Firstly: Are statins safe? There are doubts 11

but there appear to be non-doubters https://drmalcolmkendrick.org/2017/05/08/its-official-statins-do-not-have-any-side-effects/ 12

and he is referring to. Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT- LLA): a randomised double-blind placebo-controlled trial 13

but there appear to be non-doubters https://drmalcolmkendrick.org/2017/05/08/its-official-statins-do-not-have-any-side-effects/ 14

JAMA recommendations for 2017 ASCVD=Atherosclerotic Cardiovascular Disease 15

JAMA recommendations for 2017 ASCVD=Atherosclerotic Cardiovascular Disease 16

TChol / LDL / HDL / Trig ratios 17

Cholesterol elevation and heart disease are not very well correlated 18

Could high cholesterol (incl LDL) have positive effects? It would seem so 19

Many heart attack patients have normal LDL cholesterol 20

The discussion shifts towards small dense LDL https://www.docmuscles.com/category/cholesterol/ 21

What is it about small dense LDL? 22

Trigs seem to cause increase in small dense LDL particles 23

And Trigs also have an effect on HDL 24

HDL the higher the better? Not true 25

Triglycerides fluctuate http://www.clinlabnavigator.com/lipid-variability.html 26

Lipid ratios 27

There are a few lipid ratios (atherogenic indices) that are commonly used to optimise the predictive capacity of the lipid profile 28

What is a good option? If small dense LDL is the culprit..then we want to know how many small dense LDL particles there are (it is understood that testing for small dense LDL is expensive) TChol tells us, how many LDL particles are there (appr. 2/3 of all cholesterol) Triglycerides correlate with small dense LDL (but fluctuate) HDL doesn t fluctuate so much, but is inversely correlated to Trigs So how about using TChol/HDL as a ratio to gauge the number of small dense LBL particles? and therefore CVD risk? (But keep in mind the possible distortion through ultra-high Trigs and the detrimental effect of ultra-high HDL) 29

Conclusions The Statin debate is a heated one..let s keep an eye on it! Our attention is being drawn to small dense LDL particles The TChol/HDL ratio may at this stage be the most reasonable tool to gauge CVD risk 30

31

32

Legal notice 2017 Swiss Re. All rights reserved. You are not permitted to create any modifications or derivative works of this presentation or to use it for commercial or other public purposes without the prior written permission of Swiss Re. The information and opinions contained in the presentation are provided as at the date of the presentation and are subject to change without notice. Although the information used was taken from reliable sources, Swiss Re does not accept any responsibility for the accuracy or comprehensiveness of the details given. All liability for the accuracy and completeness thereof or for any damage or loss resulting from the use of the information contained in this presentation is expressly excluded. Under no circumstances shall Swiss Re or its Group companies be liable for any financial or consequential loss relating to this presentation. 33